SLC5A2 and atrial fibrillation: While this may also be true for SGLT2 inhibitors, based on the present findings, it is also possible that a difference from placebo was not detected because of the low statistical power due to the small number of episodes of incident AF and relatively short duration of follow‐up in DAPA‐HF.